Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines (1996)

Peer-Reviewed Study · Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR · October 1, 1996

Wischik CM et al., 1996-10-01: IN VITRO: methylene blue blocks tau-tau binding in the repeat domain and reverses protease resistance of paired helical filaments – the founding paper of the tau-aggregation rationale, with no amyloid arm.

We have identified a nonneuroleptic phenothiazine previously used in man (methylene blue, MB), which reverses the proteolytic stability of protease-resistant PHFs by blocking the tau-tau binding interaction through the repeat domain.

Wischik CM et al., 1996-10-01: IN VITRO: methylene blue blocks tau-tau binding in the repeat domain and reverses protease resistance of paired helical filaments – the founding paper of the tau-aggregation rationale, with no amyloid arm. IN VITRO (tau-tau binding assay, PHF preparations). Cambridge Brain Bank Laboratory, University of Cambridge. No animals, no patients. Authors state MB is inhibitory only at concentrations above those achievable clinically and that nanomolar desmethyl derivatives were sought – i.e. the paper is a tau mechanism paper, NOT an amyloid-clearance paper. Funder/COI not stated in abstract. Key for C6: the programme's mechanism is tau aggregation inhibition. Also filed as MTJ-37, MTR-045 (claims C17, C6, C8). Study type: lab.